Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples